5th Annual Pharma Pricing & Reimbursement Forum
10-11 March 2016 – Austria Trend Hotel Park Royal Palace
Vienna, Austria
Hot Topics
pharma forum
Media box
Speakers
Since 2009, Alexander Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as lawyer in his own law firm in Düsseldorf (www.natz-law.com). From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer with Sträter Law Firm in Germany with a special focus on discount agreements and licensing of pharmaceuticals. Dr. Natz also was working in the field of competition law with the European Commission and the pharmaceutical industry. As research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.
Medical Doctor by training, since 1999 different leading positions in Pharmaceutical Industry, from 2006 to 2011 Head Clinical Research and Pharmacovigilance at BPI, German Pharmaceutical Industry Association. Expertise in Pharmacoeconomy, Health Care Research, HTA and Outcomes Research. Since joining Alcon responsibility for pharmaceuticals and devices, involved in German AMNOG procedures and new regulatory framework for devices. Member in various scientific associations.
Anne-Toni is a member of AZ’s Global Payer Evidence and Pricing Leadership Team. She is responsible for Global Market Access strategy and Market access capability.
Prior to joining AstraZeneca she was a Senior Director for Baxter Healthcare, responsible for Government Relations, Market Access, Health Outcomes and Advocacy. Baxter’s portfolio includes pharmaceuticals biotechnology and medical devices.
A pharmacologist by training Anne-Toni has established several new businesses and functions; as a founding Board member she set up the National Institute for Clinical Excellence (NICE) and her career has spanned pure research, regulatory affairs, sales & marketing, market access, communications, advocacy and government & industry affairs.
Jörg Mahlich graduated in economics from the University of Kiel/Germany and holds a doctoral degree in economics from the University of Vienna/Austria. He is currently heading the health economics department at Janssen Japan in Tokyo. Previous to that he was in the market access team of Janssen (Germany) where he was involved in several German HTA submissions. He is a research affiliate at the Düsseldorf Institute for Competition Economics (DICE) of the University of Düsseldorf/Germany. Until his move to Japan, he was also teaching Economics and Health Economics at the Economics Department of the University of Vienna. He is interested in pharmaceutical economics and policy including HTA.
Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara Fabrizio Gianfrate, 51, (Rome, Italy), degree and Master in Health Economics at University of Rome, specializations in Business Management at London School of Economics, Health Economics at Stockolm Economic School, Advanced Health Economics and Pharmacoeconomics at University of York, Economic Journalism at University of Verona. Actually Professor of Healthcare and Pharmaceutical Economics, Management, Mktg and Legislation at LUISS (University and Business School of Association of Italian Manufacturers – Confindustria) in Rome and Public University of Ferrara. Editor-in-Chief of Tecnica Ospedaliera and NCF, in the past director of Aboutpharma magazine (IMS Health Group). Consultant for pharmaceutical industries at national and international level and healthcare institutions in pricing & reimbursement, policies, Mkt access, HTA, public affairs, strategic mktg, communication. Registered journalist, columnist for healthcare and pharmaceuticals newspapers and magazines. Appointed in the past as Director at Ministry of Health, role then not executed, before he was General Manager and Vice President of Smith Kline Foundation Italy, after holding several management roles in pharmaceutical industry in business and strategies, with secondments in UK and US and as member of EFPIA groups.
Oliver joined Eli Lilly in June 2001. He graduated from the Justus-Liebig University in Giessen as Diplom Kaufmann degree. Oliver started as a financial analyst and went through various assignments in the financial organization in Germany before he moved to Czech Republic as the CFO for the central European countries (Czech republic, Slovakia and Hungary). Beginning of 2012 he returned to Germany and shifted from the finance function to Market Access. His responsibility now covers all activities that lead to a successful Health Technology Assessments and reimbursement for the Lilly portfolio as well as the relationship to the payer customers at national, regional and local levels.
Before joining the Austrian Public Health Institute in 1995, Dr. Vogler worked at the Department of Social Policies at the Vienna University of Business Administration and Economics where she obtained her PhD for her thesis on care for elderly people.
She is member of the Austrian Pharmacological Society, the WHO Pharmaceutical Pricing Policies Working Group, the PIPERSKA Group on Rational Use of Medicines and the focal point for Austria in the Eurodurg group.
Dr. Dominik Tomek, PharmD., PhD., MPH, 1956, has experience in public and hospital pharmacies, government administration and regulatory agency incl. oncology hospital, Ministry of Health and Health Insurance. He is a founding member of the Slovak Society for Pharmacoeconomics, Slovak Agency for Health Technology Assessment and a founding member and the current president of ISPOR Chapter Slovakia. He was elected as director in the ISPOR Board of Directors for the term 2014 – 2016 and board member of ISPOR CEE Network.
Dr. Tomek served for many years in the Drug Committee of State Institute for Drug Control, Pricing Committee of Ministry of Finance and Reimbursement Committee of Ministry of Health. He is teaching at the Faculty of Medicine, Slovak medical university, Bratislava, Slovakia. Dr. Tomek has a doctor degree in Clinical Pharmacy, a PhD. in the field of public health and degrees of postgraduate specializations in management of public pharmacy, preparation of radiopharmaceuticals, and revision pharmacy for health insurance, pharmacoeconomics, in management of public health and in market access. He studied Market Access at the University of Lyon with Prof. Mondher Toumi in EMAUD class.
Patrick Mollon, MD, ESSEC MBA, MSc acquired his medical qualification in Lyon’s School of Medicine, France where he also gained a Masters Degree in Medical and Biological Sciences, including Pharmacology, Psychology and Medical Statistics. Prior to this, he received an MBA from the Superior School of Business and Administration and Economics (ESSEC) in Paris.
He then worked as a Clinician, practicing General Medicine as well as being a Registrar in Emergency Medicine and Intensive Care in an University Teaching Hospital in Lyon, France.
He started his Pharmaceutical Career in Pfizer Central Research as a Clinical Research Physician and then joined the Outcomes Research Division where he held a number of successive positions in the Product Development Group and the Medical division. He is currently Worldwide Director, Health Economics and Outcomes Research in the Global Patient Access Division of Novartis Pharma AG. Patrick has extensive experience in developing and implementing Health Economic strategies to support developmental compounds in a number of therapeutic areas, including Cardiovascular, Urology, Anti-Virals and Dermato-Immunology, leading the value identification and demonstration efforts for Market Access and Health Technology Assessment from a Global perspective. As such, he is leading the development of Patient Reported Outcomes tools, Health-Economic and Budget-Impact models, Value Dossiers and Real World Evidence.
Patrick has a number of publications in the area of Health-Economics and Outcomes Research, His main interests are in health-economic modelling methods and applications as well as patient-reported outcomes and decision-making.
Advisors
Schedule
DAY ONE
-
Global Market Access Trends
predicting the future• Trends and policies affecting the future of market access
• Implications for Pharma
• Considerations for the wider market access community -
Building of Market Access
Organizations• Proven decision making strategies
• How to deliver value to payers?
• Methods to ensure a successful payer-pharma relationship
• Effective collaboration for the benefit of the patient -
European budget crisis and its impact on
health care budgets• Introducing innovation with limited budgets
• How the prices have changed recently
• New reimbursement policies
• How will the future look like? -
Pricing of high-cost medicines
in a crisis?• Current pricing policies of competent authorities in European countries
• Limitations of pricing policies
• Examples of price comparisons of high-cost medicines in Europe
• Outlook: ideas for alternative pricing models
DAY TWO
-
Finding room for innovation. Disinvestment
of low-added value health technologies.• What is disinvestment
• Where to start
• Different approaches around the world
• Challenges: enablers and barriers -
The data driven
healthcare• Real world evidence – definition and acceptance differ among different stakeholders
• Big Data – acceptance for pricing and reimbursement?
• Market Access – how to improve data collection up to launch and post launch -
Access to Diabetes Medications in
Germany and Europe• Dossier effort, Endpoints, comparators & methodology in Germany and Europe
• Availability and further controls
• Economic differences in healthcare systems
• Price Referencing and implications -
Insights on HTA and the role of RWE
for MA in Japan and Asia• Following some other Asian countries Japan will introduce a new HTA system in April 2016.
• The presentation gives an overview of the current Japanese discussion on HTA.
• Potential consequences for pharmaceutical prices are discussed
6 reasons to attend
What do others say about us?
quality and informative.”
Brand Director, Market Access Tracker
Decision Resources
particularly the conference room..”
Director Global Pricing & Reimbursement
Abbott Products
Current and Past Sponsors
Who will you meet?
Senior Vice Presidents (SVP), FVPs, EVPs, Vice Presidents, Managing Directors, Executive Directors, Directors, Leads & Global Heads, Regional Heads, Group Heads & Heads as well as General Managers, Senior Managers & Managers OF:
- Market-Access
- Pricing
- Reimbursement
- Commercial Pricing
- Pricing Strategists
- Health Economics
- Outcomes Research
- Regulatory Affairs
- Governmental Affairs
- Public Affairs
- Public Policy Operations
- Operations
- Payer
- Real World Evidence
- Patient Access
- Corporate Affairs
- HEOR
- Medical Affairs
- International Coorperation & Strategic Development
- Policy & Reimbursement
- Marketing
- Business Inteligence
- Value Insight & Communication
- Real World evidence Solutions
Media partners
Clients
Venue
Venue
Official Airline Partner
FAQ
While we are not happy to see you cancel your registration, we understand that “life happens” and other obligations come up. Our refund schedule is as follows:
The client has the right to cancel his/her registration in the event.
There is a 50% liability on all conference registrations once made, whether the booking was made through our website or via e–mail/ telephone/ fax.
If the client cancels with more than 8 weeks’s advance notice, GLC shall be entitled to an amount equivalent to 50% of the conference fee and 16 EUR administration charge. In case the client has already made his/her payment, this will be deducted from the conference fee GLC has already received and the remainder will be refunded. If no conference fee has been received prior to the cancellation request, GLC will issue an invoice for the cancellation fee (the amount equivalent to 50% of the conference fee and 16 EUR administration charge), which the client must pay immediately upon receipt. No refunds are available for cancellations received with 8 week’s (or less) advance notice or in case the client fails to attend the conference. In these cases, the full amount of the conference fee must be paid.
In general no VAT is applied based on the Hungarian VAT law with the exception of individual payment [when you would like to pay from your own budget and not from the company’s budget] and for Hungarian companies where 27% VAT is applicable which is refundable at the end of the company’s fiscal year.
Our hospitality partners usually have options available for parking places, however it can change from event to event. If you would like to receive more information on parking please e-mail our colleague lara.ventoso[at]glceurope.com.
We provide a conference documentation pack which includes: conference agenda, notes pages and attendee information. Soft copies of some of the presentation are available on USB-flash-drives for each delegate. You may bring your laptop, tablet or other mobile device so you are able to review the presentations while they are being presented. Free Wi-Fi will be provided and outlets will be available for recharging computers, mobile devices and phones. We highly recommend you to bring along your business cards and a desire to learn from some of the industry’s leading experts.
The dress code is business casual. Feel free to leave the suits and ties at home this time. We do suggest you bring a sweater or dress in layers, as the conference room temperature may fluctuate.
Any of our staff members at the event will be delighted to help you. You can contact us for free via WhatsApp or Viber or any time over the phone or via e-mail or post.
1. Get the timing right. Many people are afraid to ask for training budget, because they can’t seem to find the “perfect time” to do it. Well, there’s no perfect time to ask for, but there are definitely some moments that are better than others. For instance, if your boss is about to take a two week vacation, she might be in a good mood. If he/she just lost a major account, may not be wise at that juncture.
2. Make a case for yourself
When you ask for budget, you should be prepared with specific details about what is in it for the company and your superior to send you as well as with an explanation of what you’re asking for. If you go into a meeting and just say, “I want a to get budget for a conference,” it’s likely that your request won’t be taken seriously. If you want to plan ahead, then you should be prepared to explain the following points:
This event will increase your productivity
You will need less supervision
You can bring back the knowledge to the company
1. Start by stating your accomplishments
2. Show that you’re ready for more responsibility and eager to learn
3. Follow up
In case you cannot attend for both days, you can always attend for just 1 day of the event. In this case we will send you all presentations of the 2 days. The participation fee is 70% of the original investment. In case you would like to attend the event for just 1 day please contact us on booking[at]glceurope.com
In case you are busy on 1 of the days, you certainly can split the 2 day conference with one of your colleague. All you need to do is send us an e-mail to booking[at]glceurope.com
We understand that not all senior-level professionals might be available on the dates. As the event is an annual event, most of the attendees try to postpone their engagements or send a small group from their teams to benefit from the conference.